Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Elif I Ekinci

Showing results (1-10 of 155) with videos related to

Pageof 16
Sort By:
Critical Care Clinics|February 21, 2019
New Agents for the Treatment of Type 2 DiabetesRenata Libianto, Elif I Ekinci
Internal Medicine Journal|November 1, 2024
What is the spectrum of kidney pathology associated with COVID-19?Ankita Muthya, Elif I Ekinci, Ashani Lecamwasam
The Medical Journal of Australia|January 8, 2020
Advances in type 2 diabetes therapy: a focus on cardiovascular and renal outcomesRenata Libianto, Timothy Me Davis, Elif I Ekinci
Advances in Chronic Kidney Disease|March 28, 2018
Glycemic Control as Primary Prevention for Diabetic Kidney DiseaseRichard J MacIsaac, George Jerums, Elif I Ekinci
Journal of Diabetes|October 4, 2024
Glucagon-like peptide-1 receptor agonists and kidney outcomesRichard J MacIsaac, Philippa Trevella, Elif I Ekinci
Internal Medicine Journal|February 11, 2021
Treatment implications of a delayed diagnosis of maturity-onset diabetes of the youngAleena S Ali, Fran Brown, Elif I Ekinci
Kidney International|April 11, 2014
'Progressive diabetic nephropathy. How useful is microalbuminuria?: contra'Richard J MacIsaac, Elif I Ekinci, G Jerums
American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation|January 28, 2014
Markers of and risk factors for the development and progression of diabetic kidney diseaseRichard J Macisaac, Elif I Ekinci, George Jerums
Annals of Translational Medicine|November 22, 2016
Cardio-renal protection with empagliflozinRichard J MacIsaac, George Jerums, Elif I Ekinci
Internal Medicine Journal|March 20, 2019
What is new in lipid-lowering therapies in diabetes?Yee-Ming Cheung, Richard O'Brien, Elif I Ekinci
Pageof 16

Showing results (1-10 of 155) with videos related to

Sort By:
Pageof 16
Critical Care Clinics|February 21, 2019
New Agents for the Treatment of Type 2 DiabetesRenata Libianto, Elif I Ekinci
Internal Medicine Journal|November 1, 2024
What is the spectrum of kidney pathology associated with COVID-19?Ankita Muthya, Elif I Ekinci, Ashani Lecamwasam
The Medical Journal of Australia|January 8, 2020
Advances in type 2 diabetes therapy: a focus on cardiovascular and renal outcomesRenata Libianto, Timothy Me Davis, Elif I Ekinci
Advances in Chronic Kidney Disease|March 28, 2018
Glycemic Control as Primary Prevention for Diabetic Kidney DiseaseRichard J MacIsaac, George Jerums, Elif I Ekinci
Journal of Diabetes|October 4, 2024
Glucagon-like peptide-1 receptor agonists and kidney outcomesRichard J MacIsaac, Philippa Trevella, Elif I Ekinci
Internal Medicine Journal|February 11, 2021
Treatment implications of a delayed diagnosis of maturity-onset diabetes of the youngAleena S Ali, Fran Brown, Elif I Ekinci
Kidney International|April 11, 2014
'Progressive diabetic nephropathy. How useful is microalbuminuria?: contra'Richard J MacIsaac, Elif I Ekinci, G Jerums
American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation|January 28, 2014
Markers of and risk factors for the development and progression of diabetic kidney diseaseRichard J Macisaac, Elif I Ekinci, George Jerums
Annals of Translational Medicine|November 22, 2016
Cardio-renal protection with empagliflozinRichard J MacIsaac, George Jerums, Elif I Ekinci
Internal Medicine Journal|March 20, 2019
What is new in lipid-lowering therapies in diabetes?Yee-Ming Cheung, Richard O'Brien, Elif I Ekinci
Pageof 16